CN107849007B - 比拉斯汀的晶型及其制备方法 - Google Patents

比拉斯汀的晶型及其制备方法 Download PDF

Info

Publication number
CN107849007B
CN107849007B CN201680042950.8A CN201680042950A CN107849007B CN 107849007 B CN107849007 B CN 107849007B CN 201680042950 A CN201680042950 A CN 201680042950A CN 107849007 B CN107849007 B CN 107849007B
Authority
CN
China
Prior art keywords
bilastine
crystalline form
temperature
diffraction pattern
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680042950.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN107849007A (zh
Inventor
J·L·德·里奥·佩里卡乔
M·C·普格扬内尔·瓦莱特
R·罗恩斯·洛佩兹
Y·E·阿雷东多·马丁内斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Disproquima Sa
Urquima SA
Original Assignee
Disproquima Sa
Urquima SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Disproquima Sa, Urquima SA filed Critical Disproquima Sa
Publication of CN107849007A publication Critical patent/CN107849007A/zh
Application granted granted Critical
Publication of CN107849007B publication Critical patent/CN107849007B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201680042950.8A 2015-07-24 2016-07-22 比拉斯汀的晶型及其制备方法 Active CN107849007B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201531103 2015-07-24
ESP201531103 2015-07-24
PCT/ES2016/070560 WO2017017301A1 (es) 2015-07-24 2016-07-22 Formas cristalinas de bilastina y procedimientos para su preparación

Publications (2)

Publication Number Publication Date
CN107849007A CN107849007A (zh) 2018-03-27
CN107849007B true CN107849007B (zh) 2024-08-09

Family

ID=57884122

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680042950.8A Active CN107849007B (zh) 2015-07-24 2016-07-22 比拉斯汀的晶型及其制备方法

Country Status (13)

Country Link
EP (1) EP3327012B1 (enExample)
JP (1) JP7168447B2 (enExample)
KR (1) KR102657147B1 (enExample)
CN (1) CN107849007B (enExample)
CA (1) CA2993134A1 (enExample)
CY (1) CY1124505T1 (enExample)
ES (2) ES2600827B9 (enExample)
LT (1) LT3327012T (enExample)
MX (1) MX382563B (enExample)
PL (1) PL3327012T3 (enExample)
PT (1) PT3327012T (enExample)
SI (1) SI3327012T1 (enExample)
WO (1) WO2017017301A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3452462A4 (en) * 2016-05-05 2019-10-23 MSN Laboratories Private Limited, R&D Center Solid state forms of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl)phenyl]-2-methylpropanoic acid and process for preparation thereof
EP3453384B1 (en) 2017-09-07 2020-05-27 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising bilastine
ES2835287T3 (es) 2017-12-18 2021-06-22 Tiefenbacher Alfred E Gmbh & Co Kg Composición farmacéutica de comprimido que comprende la forma polimórfica 3 de bilastina y aluminometasilicato de magnesio
EP3641735B1 (en) 2017-12-18 2021-02-24 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising bilastine form 3 and a water-soluble filler
BR112021005403A2 (pt) * 2018-09-25 2021-06-15 Glenmark Life Sciences Limited processos para a preparação de forma cristalina 2 de bilastina e para a preparação de solvato de p-xileno de bilastina, e, solvato de p-xileno de bilastina

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089425A1 (es) * 2002-04-19 2003-10-30 Faes Farma, S.A. POLIMORFO DEL ÁCIDO 4-[2-[4-[1-(2-ETOXIETIL)-1H-BENCIMIDAZOL-2-IL]-1-PIPERIDINIL]ETIL]-α, α-DIMETIL-BENCENOACÉTICO
CN103214454A (zh) * 2013-03-30 2013-07-24 北京万全德众医药生物技术有限公司 一种比拉斯汀晶型及制备方法
WO2014026657A2 (en) * 2012-08-15 2014-02-20 Zentiva, K.S A process for the preparation of a derivative of 2-methyl-2'-phenylpropionic acid using new intermediates
CN103788062A (zh) * 2014-02-17 2014-05-14 北京博泽德润医药科技开发有限公司 一种比拉斯汀晶型及其制备方法
SK50032014U1 (sk) * 2014-01-29 2014-10-03 Zentiva, K.S. Kryštalický dihydrát bilastínu
CN104151290A (zh) * 2014-06-30 2014-11-19 北京万全德众医药生物技术有限公司 一种制备比拉斯汀新晶型的方法
CN104447683A (zh) * 2013-09-12 2015-03-25 天津市汉康医药生物技术有限公司 一种稳定的比拉斯汀化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2124167B1 (es) * 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
CN104447682A (zh) * 2013-09-12 2015-03-25 天津市汉康医药生物技术有限公司 比拉斯汀化合物
CN104177331B (zh) * 2014-09-10 2016-08-17 北京科莱博医药开发有限责任公司 比拉斯汀的制备方法
CN104530002B (zh) * 2015-01-29 2017-06-09 天津梅花生物医药科技有限公司 比拉斯汀化合物及其制备方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089425A1 (es) * 2002-04-19 2003-10-30 Faes Farma, S.A. POLIMORFO DEL ÁCIDO 4-[2-[4-[1-(2-ETOXIETIL)-1H-BENCIMIDAZOL-2-IL]-1-PIPERIDINIL]ETIL]-α, α-DIMETIL-BENCENOACÉTICO
WO2014026657A2 (en) * 2012-08-15 2014-02-20 Zentiva, K.S A process for the preparation of a derivative of 2-methyl-2'-phenylpropionic acid using new intermediates
CN103214454A (zh) * 2013-03-30 2013-07-24 北京万全德众医药生物技术有限公司 一种比拉斯汀晶型及制备方法
CN104447683A (zh) * 2013-09-12 2015-03-25 天津市汉康医药生物技术有限公司 一种稳定的比拉斯汀化合物
SK50032014U1 (sk) * 2014-01-29 2014-10-03 Zentiva, K.S. Kryštalický dihydrát bilastínu
CN103788062A (zh) * 2014-02-17 2014-05-14 北京博泽德润医药科技开发有限公司 一种比拉斯汀晶型及其制备方法
CN104151290A (zh) * 2014-06-30 2014-11-19 北京万全德众医药生物技术有限公司 一种制备比拉斯汀新晶型的方法

Also Published As

Publication number Publication date
CA2993134A1 (en) 2017-02-02
ES2874577T3 (es) 2021-11-05
CN107849007A (zh) 2018-03-27
WO2017017301A1 (es) 2017-02-02
ES2600827B1 (es) 2017-11-24
MX382563B (es) 2025-03-13
SI3327012T1 (sl) 2021-10-29
EP3327012A4 (en) 2018-12-19
PL3327012T3 (pl) 2021-11-22
JP2018522945A (ja) 2018-08-16
RU2018104258A3 (enExample) 2019-12-25
EP3327012B1 (en) 2021-03-17
LT3327012T (lt) 2021-09-10
BR112018001225A2 (pt) 2018-09-11
KR20180036722A (ko) 2018-04-09
ES2600827A1 (es) 2017-02-10
ES2600827A8 (es) 2017-06-15
RU2018104258A (ru) 2019-08-26
KR102657147B1 (ko) 2024-04-12
PT3327012T (pt) 2021-06-21
JP7168447B2 (ja) 2022-11-09
ES2600827B9 (es) 2018-03-28
CY1124505T1 (el) 2022-07-22
MX2018000883A (es) 2018-08-15
EP3327012A1 (en) 2018-05-30

Similar Documents

Publication Publication Date Title
CN107849007B (zh) 比拉斯汀的晶型及其制备方法
JP5134552B2 (ja) ジヒドロプテリジノン誘導体の三塩酸塩形及び調製方法
KR102522895B1 (ko) Jak 키나아제 억제제 바이설페이트의 결정형 및 이의 제조방법
CN104797566A (zh) 沃替西汀氢溴酸盐的新结晶形式
TW201213325A (en) Crystalline forms of pyrimidio [6,1-A] isoquinolin-4-one compounds
TW202200594A (zh) 一種glp-1受體激動劑的晶型a及其製備方法
KR20170057441A (ko) Jak 억제제의 바이설페이트의 결정형 및 이의 제조방법
CN101568531A (zh) Mglur5受体拮抗剂的多晶型物
CN101111481A (zh) 制备结晶阿立哌唑的方法
JP2015508090A (ja) 固体形態のダビガトランエテキシレートメシレート及びその調製方法
KR20030042038A (ko) 온단세트론 히드로클로라이드의 신규한 결정 형태 및용매화물 형태와 이들의 제조 방법
JP2005534633A (ja) ガチフロキサシンの新規結晶形
JP6908657B2 (ja) ４−［２−ジメチルアミノ−１−（１−ヒドロキシシクロヘキシル）エチル］フェニル４−メチルベンゾエートヒドロクロリドの多形体、それらを作製する方法及びそれらの使用
CN1880294B (zh) 右酮洛芬氨丁三醇的多晶型、其制备方法和包含它的组合物
RU2772222C2 (ru) Кристаллические формы биластина и способы их получения
US20040038985A1 (en) Crystal forms of 1- [6-chloro-5-(trifluoromethly) -2-pyridinyl] piperazine hydrochloride
TWI378929B (en) Crystalline 1h-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1h-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses
CN111320596A (zh) 盐酸美呋哌瑞多晶型物及其制备方法
WO2025130951A1 (zh) Ad-35多晶型物及其制备方法和用途
BR112018001225B1 (pt) Forma cristalina eta de bilastina hidratada, métodos de preparação da mesma, composição farmacêutica compreendendo dita forma cristalina e uso desta para tratar processos de doença mediados por histamina e reações alérgicas
JP2009527544A (ja) ベシピルジン塩酸塩の結晶形態、その製造方法および使用
CN103755765B (zh) 醋酸乌利司他的多晶型及其制备方法
JPH10503532A (ja) レソピトロン二塩酸塩の新規多形およびその水和形その製造方法およびそれを含有する組成物
WO2019053491A1 (en) CRYSTALLINE BENIDIPINE HCL SOLID FORMS AND PROCESSES FOR PREPARING THE SAME

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant